Quantinno Capital Management LP boosted its holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 610.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 336,527 shares of the company's stock after buying an additional 289,141 shares during the period. Quantinno Capital Management LP owned approximately 0.13% of Maravai LifeSciences worth $2,797,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD lifted its stake in shares of Maravai LifeSciences by 5.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 73,595 shares of the company's stock valued at $639,000 after purchasing an additional 3,575 shares during the period. GAMMA Investing LLC increased its holdings in Maravai LifeSciences by 310.2% in the second quarter. GAMMA Investing LLC now owns 3,585 shares of the company's stock valued at $26,000 after purchasing an additional 2,711 shares during the last quarter. Blue Trust Inc. acquired a new position in Maravai LifeSciences in the second quarter valued at about $44,000. Bank of New York Mellon Corp boosted its holdings in Maravai LifeSciences by 30.1% during the second quarter. Bank of New York Mellon Corp now owns 506,413 shares of the company's stock worth $3,626,000 after buying an additional 117,120 shares during the last quarter. Finally, Liontrust Investment Partners LLP grew its position in shares of Maravai LifeSciences by 14.7% during the 2nd quarter. Liontrust Investment Partners LLP now owns 43,845 shares of the company's stock worth $314,000 after buying an additional 5,628 shares during the period. 50.25% of the stock is owned by institutional investors.
NASDAQ:MRVI opened at $5.43 on Tuesday. The company has a market cap of $1.37 billion, a P/E ratio of -3.31 and a beta of -0.08. Maravai LifeSciences Holdings, Inc. has a twelve month low of $4.28 and a twelve month high of $11.56. The business has a 50 day moving average price of $6.74 and a two-hundred day moving average price of $7.90. The company has a quick ratio of 9.94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89.
MRVI has been the topic of a number of analyst reports. William Blair reiterated a "market perform" rating on shares of Maravai LifeSciences in a research report on Friday, November 8th. Royal Bank of Canada reduced their price target on shares of Maravai LifeSciences from $17.00 to $13.00 and set an "outperform" rating on the stock in a research report on Friday, November 8th. Wolfe Research assumed coverage on shares of Maravai LifeSciences in a report on Thursday, November 14th. They issued a "peer perform" rating for the company. The Goldman Sachs Group downgraded Maravai LifeSciences from a "neutral" rating to a "sell" rating and dropped their price objective for the stock from $7.00 to $4.25 in a research note on Thursday, December 5th. Finally, Wells Fargo & Company started coverage on Maravai LifeSciences in a research note on Tuesday, August 27th. They issued an "overweight" rating and a $10.00 target price for the company. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $10.03.
View Our Latest Stock Report on Maravai LifeSciences
In related news, insider Carl Hull bought 175,000 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were acquired at an average price of $5.64 per share, with a total value of $987,000.00. Following the completion of the transaction, the insider now owns 175,000 shares in the company, valued at $987,000. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.63% of the stock is currently owned by corporate insiders.
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Maravai LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.
While Maravai LifeSciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.